CA2407046A1 - Immunoregulator - Google Patents
Immunoregulator Download PDFInfo
- Publication number
- CA2407046A1 CA2407046A1 CA002407046A CA2407046A CA2407046A1 CA 2407046 A1 CA2407046 A1 CA 2407046A1 CA 002407046 A CA002407046 A CA 002407046A CA 2407046 A CA2407046 A CA 2407046A CA 2407046 A1 CA2407046 A1 CA 2407046A1
- Authority
- CA
- Canada
- Prior art keywords
- immunoregulator
- immune
- disorder
- peptide
- mediated disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease or inflammatory disease. The invention provides among others an immunoregulator (NMPF), use of an NMPF in preparing a pharmaceutical composition for treating an immune-mediated disorder, a pharmaceutical composition and a method for treating an immune-mediated disorder.
Claims (44)
1. An immunoregulator obtainable or derivable from beta-HCG capable of regulating Th1 and/or Th2 cell activity.
2. An immunoregulator according to claim 1 capable of modulating dendritic cell differentiation.
3. An immunoregulator according to claim 1 capable of protecting a mouse against a lipopolysaccharide induced septic shock.
4. An immunoregulator according to claim 1 to 3 obtainable from nicked beta-hCG or beta-core hCG.
5. An immunoregulator according to anyone of claims 1 to 4 which comprises a peptide having an amino acid sequence MTRVLQGVLPALPQVVC or functional fragment or functional analogue thereof.
6. An immunoregulator according to claim 5 wherein said functional fragment comprises an amino acid sequence LQGVLPALPQVVC or functional analogue thereof.
7. An immunoregulator according to 6 wherein said functional fragment comprises an amino acid sequence VLPALPQVVC or LQGVLPALPQ or functional analogue thereof.
8. An immunoregulator according to claim 7 wherein said functional fragment comprises an amino acid sequence VLPALPQ or GVLPALPQ or GVLPALP or VLPALP or QVVC or PALP
or LQGV or MTRV or VVC or MTR or LQG or functional analogue thereof.
or LQGV or MTRV or VVC or MTR or LQG or functional analogue thereof.
9. An immunoregluator according to any of the preceding claims wherein one or more amino acids have been replaced by an alanine residue.
10. An immunoregulator according to claims 8 or 9 capable of protecting a mouse against a lipopoly-saccharide induced septic shock or diabetes or Experimental Auto-immune Encephalitis/multiple sclerosis.
21. Use of an immunoregulator according to anyone of claims 1-10 for the production of a pharmaceutical composition for the treatment of an immune-mediated-disorder.
12. Use according to claim 11 wherein said immune-mediated disorder comprises chronic inflammation, such as diabetes, multiple sclerosis or acute or chronic a transplant rejection.
13. Use according to claim 11 wherein said immune-mediated disorder comprises acute inflammation, such as septic or anaphylactic shock or hyper-acute transplant rejection.
14. Use according to claim 11 wherein said immune-mediated disorder comprises auto-immune disease, such as systemic lupus erythematosus or rheumatoid arthritis.
15. Use according to claim 11 wherein said immune-mediated disorder comprises allergy, such as asthma or parasitic disease.
16. Use according to claim 11 wherein said immune-mediated disorder comprises an overly strong immune response directed against an infectious agent, such as a virus or bacterium.
17. Use according to claim 11 wherein said immune-mediated disorder comprises pre-eclampsia or another pregnancy related immune-mediated disorder.
18. Use according to claim 12 to 17 wherein said treatment comprises regulating relative ratios and/or cytokine activity of lymphocyte, dendritic or antigen presenting cell subset-populations in a treated individual.
19. Use according to claim 18 wherein said subset populations comprise Th1 or Th2, or DC1 or DC2 cells.
20. Use according to anyone of claims 12 to 19 wherein said immunoregulator comprises a hCG preparation or a fraction derived thereof.
21. A pharmaceutical composition for treating an immune-mediated disorder comprising an immunoregulator according to anyone of claims 1 to 10.
22. A pharmaceutical composition for treating an immune-mediated disorder comprising an active component obtainable from a urinary metabolite of HCG capable of protecting a mouse against a lipopolysaccharide induced septic shock or diabetes or Experimental Auto-immune Encephalitis/multiple sclerosis.
23. A method for treating an immune-mediated-disorder comprising subjecting an animal to treatment with at least one immunoregulator according to any one of claims 1 to 10.
24. A method according to claim 23 wherein said disorder comprises diabetes.
25. A method according to claim 23 wherein said disorder comprises sepsis.
26. A method according to any one of claims 24 or 25 further comprising regulating relative ratios and/or cytokine activity of lymphocyte, dendritic or antigen presenting cell subset-populations in said animal.
27. A method according to claim 26 wherein said subset-populations comprise Th1 or Th2, or DC1 or DC2 cells.
28. A method according to any one of the claims 23-27, wherein the immunoregulator is used in combination with a targeting agent, such as a monoclonal antibody, for controlled and/or localized delivery.
29. Use of an immunoregulator according to any of the claims 1-10 for the manufacture of a medicament for modulating a cardiovascular or circulatory disorder, in particular a pregnancy related cardiovascular or circulatory disorder.
30. A pharmaceutical composition for modulating a cardiovascular or circulatory disorder, in particular a pregnancy related cardiovascular or circulatory disorder, comprising an immunoregulator according to any of the claims 1-10.
31. A method for modulating a cardiovascular or circulatory disorder, in particular a pregnancy related cardiovascular or circulatory disorder, comprising subjecting an animal to treatment with at least one immunoregulator according to any of the claims 1-10.
32. A method for diagnosing a pregnancy related immune-mediated disorder, such as pre-eclampsia, or other immune-mediated disorder comprising determining in a sample, preferably a urine or blood sample, the relative ratio of a relative long-chain peptide versus a relative short-chain peptide, said peptides derivable from breakdown of beta-HCG.
33. A method according to claim 32 comprising determining the relative ratio of a relative long-chain peptide versus a relative short-chain peptide derived from breakdown a peptide having an amino acid sequence MTRVLQGVLPALPQVVC.
34. A method according to claim 33 wherein said relative long-chain peptide comprises an amino acid sequence LQGVLPALPQ or GVLPALPQ or VLPALPQ or GVLPALP or VLPALP.
35. A method according to claim 32 or 33 wherein said relative short-chain peptide comprises MTRV or MTR or PALP or QWC or VVC, or LQGV or LQG.
36. A method for diagnosing a pregnancy related immune-mediated disorder, such as pre-eclampsia, or other immune-mediated disorder comprising determining in a sample, preferably a urine or blood sample, the relative ratio of a septic shock enhancing peptide versus a septic shock decreasing peptide, said peptides being derivable from breakdown of beta-HCG.
37. A method for diagnosing a pregnancy related immune-mediated disorder, such as pre-eclampsia, or other immune-mediated disorder comprising determining in a sample, preferably a urine or blood sample, the relative ratio of a diabetes enhancing peptide versus a diabetes decreasing peptide, said peptides being derivable from breakdown of beta-HCG.
38. A method for diagnosing a cardiovascular disorder comprising determining in a sample, preferably a urine or blood sample, the relative ratio of a heart failure enhancing peptide versus a heart failure decreasing peptide, said peptides being derivable from breakdown of beta-HCG.
39. A method for selecting an immunoregulator comprising determining therapeutic effect of an immunoregulator by subjecting an animal prone to show signs of diabetes to a peptide composition or fraction thereof, and determining the development of diabetes in said animal.
40. A method for selecting an immunoregulator comprising determining therapeutic effect of an immunoregulator by subjecting an animal prone to show signs of septic shock to a peptide composition or fraction thereof and determining the development of septic shock in said animal.
41. A method according to claim 39 or 40 wherein said therapeutic effect is further measured by determining relative ratios and/or cytokine activity of lymphocyte, dendritic or antigen presenting cell subset-populations in said animal.
42. A method according to claim 41 wherein said therapeutic effect is further measured by determining enzyme levels in said animal.
43. An immunoregulator selected by a method according to anyone of claims 39 to 42.
44. A pharmaceutical composition comprising an immunoregulator according to claim 43.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00201139.3 | 2000-03-29 | ||
EP00201139A EP1138692A1 (en) | 2000-03-29 | 2000-03-29 | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
PCT/NL2001/000259 WO2001072831A2 (en) | 2000-03-29 | 2001-03-29 | Immunoregulator |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2407046A1 true CA2407046A1 (en) | 2001-10-04 |
CA2407046C CA2407046C (en) | 2011-02-15 |
Family
ID=8171269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2407046A Expired - Lifetime CA2407046C (en) | 2000-03-29 | 2001-03-29 | Immunoregulator |
Country Status (18)
Country | Link |
---|---|
US (2) | US7365155B2 (en) |
EP (3) | EP1138692A1 (en) |
JP (1) | JP5172064B2 (en) |
KR (1) | KR100800876B1 (en) |
AT (2) | ATE411340T1 (en) |
AU (1) | AU781632B2 (en) |
CA (1) | CA2407046C (en) |
CY (2) | CY1108706T1 (en) |
DE (2) | DE60136577D1 (en) |
DK (2) | DK1272515T3 (en) |
ES (2) | ES2315278T3 (en) |
HK (1) | HK1052360B (en) |
IL (2) | IL151945A0 (en) |
NZ (1) | NZ521703A (en) |
PT (2) | PT1887016E (en) |
SG (1) | SG127739A1 (en) |
SI (2) | SI1272515T1 (en) |
WO (1) | WO2001072831A2 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
US8680059B2 (en) | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
US6844315B2 (en) | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
KR101184833B1 (en) * | 2003-04-08 | 2012-09-20 | 바이오템프트, 비.브이. | Compositions for mucosal and oral administration comprising HCG fragments |
EP1466613A1 (en) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Compositions for mucosal and oral administration comprising hCG fragments |
US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
EP1466611A1 (en) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Use of HCG derived peptides in the treatment of iatrogenic diseases |
EP1466612A1 (en) * | 2003-04-08 | 2004-10-13 | Biotempt B.V. | Treatment of inflammation and sepsis with hCG derived peptides |
US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
WO2006090874A1 (en) * | 2005-02-25 | 2006-08-31 | Nihon University | Method of analyzing mammalian t cell cytokines, method of evaluating all of related diseases and analysis of prevention and therapy therefor |
KR20080033331A (en) | 2005-07-05 | 2008-04-16 | 바이오템프트, 비.브이. | Treatment of tumors |
DE102005054454A1 (en) * | 2005-11-09 | 2007-06-28 | Universität Duisburg-Essen | Use of chorionic gonadotropin as immunosuppressant |
EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
CA2677948C (en) * | 2007-02-12 | 2014-12-09 | Biotempt B.V. | Treatment of trauma-hemorrhage with short oligopeptides |
US20080217002A1 (en) * | 2007-03-07 | 2008-09-11 | Floyd Randolph Simonds | Sand control screen having a micro-perforated filtration layer |
WO2009085180A1 (en) * | 2007-12-20 | 2009-07-09 | The Feinstein Institute For Medical Research | Treatment of sepsis and inhibition of mif by d-t4 |
EP2109054A1 (en) | 2008-04-09 | 2009-10-14 | Biotempt B.V. | Methods for identifying biologically active peptides and predicting their function |
EP2490021A1 (en) | 2011-02-18 | 2012-08-22 | Biotempt B.V. | Modulators of PRR and GPCR signalling |
CN104415162B (en) * | 2013-08-21 | 2018-05-15 | 常州市肿瘤医院 | Treat Chinese medicine composition of leukopenia after chemoradiotherapy and preparation method thereof |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4571336A (en) | 1983-08-25 | 1986-02-18 | Endorphin, Inc. | Immune stimulation |
US4977244A (en) * | 1985-06-27 | 1990-12-11 | The United States Of America As Represented By The Department Of Health And Human Services | Uromodulin and a process of purifying it |
US4855285A (en) * | 1985-12-04 | 1989-08-08 | The Ohio State University Research Foundation | Antigenic modification of polypeptides |
DK237187A (en) | 1986-05-12 | 1987-11-13 | Wellcome Found | PHARMACEUTICAL USE OF T-PA |
US5055447A (en) | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
US5308834A (en) | 1989-02-14 | 1994-05-03 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and prevention thereof using a BPI protein |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
US6051596A (en) | 1990-08-10 | 2000-04-18 | Anormed, Inc. | Immunosuppressive compositions |
US5958413A (en) * | 1990-11-01 | 1999-09-28 | Celltech Limited | Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor |
EP0584238A1 (en) | 1991-05-17 | 1994-03-02 | Chiron Corporation | INHIBITOR OF NF-$g(k)B TRANSCRIPTIONAL ACTIVATOR AND USES THEREOF |
DE4138621A1 (en) * | 1991-11-25 | 1993-06-17 | Boehringer Ingelheim Int | METHOD FOR SCREENING SUBSTANCES WITH MODULATING EFFECT ON A RECEPTACLE-RELATED CELLULAR SIGNAL TRANSMISSION PATH |
ATE260971T1 (en) * | 1992-04-01 | 2004-03-15 | Univ Rockefeller | METHOD FOR THE IN VITRO CULTIVATION OF DENDRITIC PRECURSOR CELLS AND THEIR USE FOR IMMUNOGENIC PRODUCTION |
DE69219590T2 (en) | 1992-05-30 | 1997-11-27 | Sikiric Predrag | BPC peptides, their production and use |
US5436270A (en) | 1993-04-07 | 1995-07-25 | National Science Council | Method for protecting against endotoxin-induced shock |
US5380668A (en) * | 1993-07-06 | 1995-01-10 | University Of Utah Research Foundation | Compounds having the antigenicity of hCG |
US5837478A (en) | 1993-12-23 | 1998-11-17 | Icos Corporation | Method of identifying modulators of binding between and VCAM-1 |
US5677275A (en) | 1994-08-05 | 1997-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
US5851997A (en) * | 1994-10-04 | 1998-12-22 | Harris; Pamela Jo | Use of human chorionic gonadotropin as an immune-potentiating antiviral agent |
US5700781A (en) | 1994-10-04 | 1997-12-23 | Harris; Pamela Jo | Method for treating Kaposi's sarcoma and HIV infections |
SE520730C2 (en) | 1995-01-20 | 2003-08-19 | Eskil Elmer | Treatment of brain ischemia and brain damage with a neuroprotective drug |
EP0867448A4 (en) | 1995-04-13 | 2000-04-26 | Chugai Pharmaceutical Co Ltd | PEPTIDE SUPPRESSING IxBalpha PHOSPHORYLATION |
AU5161296A (en) | 1995-04-21 | 1996-11-07 | Allelix Biopharmaceuticals Inc. | Anti-haemorrhagic peptides |
US6361992B1 (en) * | 1996-05-08 | 2002-03-26 | The United States Of America As Represented By The Department Of Health And Human Services | Thyroid stimulating hormone superagonists |
US5968513A (en) | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
AU3587797A (en) * | 1996-06-24 | 1998-01-14 | University Of Maryland Biotechnology Institute | Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin |
US5997871A (en) * | 1996-06-24 | 1999-12-07 | University Of Maryland Biotechnology Insitute | Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin |
US6150500A (en) | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
GB9617021D0 (en) | 1996-08-13 | 1996-09-25 | Salpep Biotechnology Inc | Novel peptides for treatment of inflammation and shock |
JP2001511649A (en) | 1997-02-07 | 2001-08-14 | トーマス・ジェファーソン・ユニバーシティ | Peptidomimetic of cytokine receptor gamma chain |
CA2281224A1 (en) | 1997-02-15 | 1998-08-20 | Proscript, Inc. | Treatment of infarcts through inhibition of nf-kappab |
US5801193A (en) | 1997-04-15 | 1998-09-01 | Immune Modulation, Inc. | Compositions and methods for immunosuppressing |
US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
DE19735587B4 (en) | 1997-08-16 | 2012-03-22 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | A peptide having a radioprotective effect, a cosmetic or pharmaceutical composition containing the same, a nucleic acid encoding the same, a preparation process for this peptide and the use as a radioprotective agent |
HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
WO1999031227A2 (en) | 1997-12-12 | 1999-06-24 | The University Of Western Ontario | NOVEL PEPTIDE, apoEp1.B, COMPOSITIONS AND USES THEREOF |
US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
ATE249835T1 (en) * | 1998-05-20 | 2003-10-15 | Univ Erasmus | IMMUNOREGULATOR |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US7175679B2 (en) * | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
RU2139085C1 (en) | 1998-06-23 | 1999-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Agent stimulating reparative processes and method of its use |
WO2000017348A1 (en) | 1998-09-17 | 2000-03-30 | Hopital Sainte-Justine | G protein-coupled receptor agonists or antagonists |
EP1131351A2 (en) | 1998-11-20 | 2001-09-12 | Mount Sinai Hospital | Peptides that modulate the interaction of b class ephrins and pdz domains |
US6507788B1 (en) | 1999-02-25 | 2003-01-14 | Société de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.) | Rational selection of putative peptides from identified nucleotide, or peptide sequences, of unknown function |
CA2366678A1 (en) | 1999-03-09 | 2000-09-14 | Fornix Biosciences N.V. | Synthetic complementary peptides and ophthalmologic uses thereof |
US20030148955A1 (en) | 1999-04-19 | 2003-08-07 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
RU2157233C1 (en) * | 1999-05-11 | 2000-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Tetrapeptide showing geroprotective activity, pharmacological agent based on thereof and method of its use |
US7994278B1 (en) | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
MXPA02001349A (en) | 1999-08-09 | 2002-07-22 | Tripep Ab | Protein polymerization inhibitors and methods of use. |
US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
EP1222199A4 (en) | 1999-10-15 | 2003-03-12 | Histatek Llc | N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent |
RU2155063C1 (en) | 1999-10-20 | 2000-08-27 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Tetrapeptide stimulating functional activity of neurons, pharmacological agent based on thereof and method of its use |
EP2368898B1 (en) | 1999-11-18 | 2014-10-01 | Ischemix, Inc | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
EP1263778B1 (en) | 2000-01-14 | 2005-04-27 | Richard S. Larson | Peptide inhibitors of lfa-1/icam-1 interaction |
CA2400187A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
WO2001068113A1 (en) | 2000-03-10 | 2001-09-20 | Monsanto Technology Llc | Anti-hypertensive peptides |
US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
EP1300418A1 (en) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US6783757B2 (en) * | 2000-06-01 | 2004-08-31 | Kirkman Group, Inc. | Composition and method for increasing exorphin catabolism to treat autism |
US6586403B1 (en) | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
US20020155106A1 (en) | 2000-12-01 | 2002-10-24 | Hammond David J. | Method of identifying a ligand for a target molecule |
US20040198652A1 (en) | 2001-04-24 | 2004-10-07 | Carter J. Paul | Methods and compositions for preventing and treating septic shock and endotoxemia |
US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
US7501391B2 (en) * | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US7135286B2 (en) * | 2002-03-26 | 2006-11-14 | Perlegen Sciences, Inc. | Pharmaceutical and diagnostic business systems and methods |
AU2003225008A1 (en) | 2002-04-15 | 2003-11-03 | American National Red Cross | Plasma protein-binding ligands |
US7517529B2 (en) | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
KR20080033331A (en) | 2005-07-05 | 2008-04-16 | 바이오템프트, 비.브이. | Treatment of tumors |
EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
-
2000
- 2000-03-29 EP EP00201139A patent/EP1138692A1/en active Pending
-
2001
- 2001-03-29 CA CA2407046A patent/CA2407046C/en not_active Expired - Lifetime
- 2001-03-29 DK DK01922133T patent/DK1272515T3/en active
- 2001-03-29 AT AT01922133T patent/ATE411340T1/en active
- 2001-03-29 WO PCT/NL2001/000259 patent/WO2001072831A2/en active IP Right Grant
- 2001-03-29 PT PT07108784T patent/PT1887016E/en unknown
- 2001-03-29 SI SI200130892T patent/SI1272515T1/en unknown
- 2001-03-29 DK DK07108784T patent/DK1887016T3/en active
- 2001-03-29 NZ NZ521703A patent/NZ521703A/en not_active IP Right Cessation
- 2001-03-29 SG SG200405399A patent/SG127739A1/en unknown
- 2001-03-29 JP JP2001571762A patent/JP5172064B2/en not_active Expired - Fee Related
- 2001-03-29 KR KR1020027012952A patent/KR100800876B1/en active IP Right Grant
- 2001-03-29 PT PT01922133T patent/PT1272515E/en unknown
- 2001-03-29 ES ES01922133T patent/ES2315278T3/en not_active Expired - Lifetime
- 2001-03-29 DE DE60136577T patent/DE60136577D1/en not_active Expired - Lifetime
- 2001-03-29 AU AU48913/01A patent/AU781632B2/en not_active Expired
- 2001-03-29 DE DE60136169T patent/DE60136169D1/en not_active Expired - Lifetime
- 2001-03-29 ES ES07108784T patent/ES2317620T3/en not_active Expired - Lifetime
- 2001-03-29 EP EP07108784A patent/EP1887016B1/en not_active Expired - Lifetime
- 2001-03-29 EP EP01922133A patent/EP1272515B1/en not_active Expired - Lifetime
- 2001-03-29 IL IL15194501A patent/IL151945A0/en unknown
- 2001-03-29 AT AT07108784T patent/ATE414104T1/en active
- 2001-03-29 SI SI200130895T patent/SI1887016T1/en unknown
-
2002
- 2002-09-26 IL IL151945A patent/IL151945A/en active IP Right Grant
- 2002-09-30 US US10/262,522 patent/US7365155B2/en not_active Ceased
-
2003
- 2003-06-27 HK HK03104599.4A patent/HK1052360B/en not_active IP Right Cessation
-
2009
- 2009-01-13 CY CY20091100022T patent/CY1108706T1/en unknown
- 2009-02-03 CY CY20091100124T patent/CY1110259T1/en unknown
-
2011
- 2011-03-17 US US13/065,318 patent/USRE43140E1/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2407046A1 (en) | Immunoregulator | |
Li et al. | Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia | |
Codarri et al. | Cytokine networks in multiple sclerosis: lost in translation | |
Yoshida et al. | Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants | |
Renz et al. | Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen-induced sensitization. | |
Di Meglio et al. | The multitasking organ: recent insights into skin immune function | |
CO5611161A2 (en) | TREAT IMMUNE DISORDER USING INTERLEUCINE AGONISTS-21 / INTERLEUCINE RECEIVER-21 | |
Fisher et al. | Increased CCN2, substance P and tissue fibrosis are associated with sensorimotor declines in a rat model of repetitive overuse injury | |
Sebastiani et al. | Nickel-specific CD4+ and CD8+ T cells display distinct migratory responses to chemokines produced during allergic contact dermatitis | |
Herro et al. | The control of tissue fibrosis by the inflammatory molecule LIGHT (TNF Superfamily member 14) | |
Atzeni et al. | Anti-IL-17 agents in the treatment of axial spondyloarthritis | |
US20190209651A1 (en) | Osteoarthritis Treatment With Chemokine-Loaded Alginate Microparticles | |
Adelman et al. | Elevated serum interleukin-6 associated with a failur in B cell differentiation in common variable immunodeficiecy | |
WO2005007836A1 (en) | Regulatory t-cells containing galectins for the therapy and diagnosis of diseases | |
Kim et al. | Water-soluble chitosan-based antisense oligodeoxynucleotide of interleukin-5 for treatment of allergic rhinitis | |
JP2004501088A5 (en) | ||
Wang et al. | An alternate STAT6-independent pathway promotes eosinophil influx into blood during allergic airway inflammation | |
Martin et al. | IFN-γ is necessary but not sufficient for anti-CD40 antibody-mediated inhibition of the Th2 response to Schistosoma mansoni eggs | |
CN1816353B (en) | Medicinal composition for preventing or treating Th1 type immunological disease | |
Mäurer et al. | Relapsing-remitting multiple sclerosis: what is the potential for combination therapy? | |
Pohlers et al. | Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis | |
TWI702290B (en) | Modified natural killer t cells, pharmaceutical compositions and uses thereof | |
WO2020244345A1 (en) | Purified double negative t cell and preparation and use thereof | |
Shang et al. | Regulation of antigen-specific versus by-stander IgE production after antigen sensitization | |
Grabarek et al. | The capability to forecast response to therapy with regard to the time and intensity of the inflammatory process in vitro in dermal fibroblasts induced by IL-12 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20210329 |